Jonny was here petartdas.com It's a problem that Merck and other companies developing new immunotherapy drugs will have to solve. The drugs, including Merck's MK-3475 and Bristol-Myers' nivolumab, help the immune system fight cancer cells by disabling a protein called "programmed death 1" or PD-1 that acts as a brake on the body's ability to detect them.